Skip To Content



June 6, 2024

June 6, 2024

Cystic Fibrosis Canada has opened its annual grant competition for 2024. Canadian researchers with an interest in cystic fibrosis (CF), including its connection to diabetes and cancer, can now apply for funding to be awarded starting in early 2025.

Applications are currently being accepted in five categories:

  • Basic science and clinical research grants yield incremental gains in knowledge and practice and can lead to breakthroughs in treatment and care.
  • Early career investigator awards and research fellowships invest in tomorrow’s research leaders by providing salary support to work under the supervision of an established research or start their own labs.
  • Seed grants balance higher-risk, more innovative work with lower budgets and shorter timeframes to bring fresh new ideas to the field.

For the first time, Cystic Fibrosis Canada has partnered with the Canadian Cancer Society and Diabetes Canada who are each providing funding for seed grants that will focus on CF and cancer risk and on CF-related diabetes respectively. This pooled funding reflects that as people live longer with CF due to life-changing treatments, they are at greater risk of these complications that have not been extensively studied in CF.

Eligible proposals received by the application deadline will be peer reviewed by a panel of scientific experts and Canadians with lived experience with CF. The highest-ranked applications will be awarded grants based on funds available as a result of fundraising and donations.

In addition, Cystic Fibrosis and Génome Québec will soon be opening a separate research competition geared to Québec-based CF researchers focused on omics research investigating specific types of biomolecules.

Earlier this year, Cystic Fibrosis Canada announced the recipients of its 2023 research grant competition, awarding more than $2 million in funding for nine projects addressing various aspect of CF.

Cystic Fibrosis Canada’s research funding is grounded in a strategic approach that prioritizes listening to and working with Canadians whose lives are most affected by CF; attracting scientific minds to fuel innovation; investing in areas of unmet need; and creating impact sooner rather than later. While the median age of survival has increased among Canadians with CF, life with the disease is still too challenging and too short. Research continues to be essential in fueling progress, particularly for those who cannot benefit from life-changing therapies and those experiencing more severe complications as they age with the disease.

Information about the 2024 grant competition is available on Cystic Fibrosis Canada’s website.


Dr. Rachel Syme
Program Director, Research
Cystic Fibrosis Canada

Back to Listing